Cellak Bio completes 73.8 billion won filler plant in Wonju, with annual capacity of 16 million units

Cellak Bio has completed a 73.8 billion won filler production facility in Wonju Enterprise City, Gangwon Province, and is moving ahead with its global aesthetics contract development and manufacturing organization (CDMO) business.

Cellak Bio said it held a completion ceremony for the newly built plant in Wonju Enterprise City on Sept. 30, 2026. The facility has aseptic filling infrastructure capable of producing more than 16 million dermal fillers annually.

Construction began in February last year, and the plant was completed last April after about 1 year and 2 months of work. It is currently undergoing Good Manufacturing Practice (GMP) certification. Once certification is complete, the company plans to begin mass production and expand its contract manufacturing (CMO) and CDMO businesses targeting global partners.

Cellak Bio was founded in 2024 by key executives including Dr. Kyung-yup Moon and CEO Jae-hyuk Lee, who co-founded South Korean botulinum toxin and filler company Hugel. In its early stages, the company raised about 54 billion to 58 billion won in Series A funding to build large-scale production infrastructure ahead of demand.

The newly built plant is located on a 10,243-square-meter site in the Sinpyeong-ro area of Jijeong-myeon, Wonju, and has three above-ground floors and a total floor area of 4,584 square meters. The company plans to focus on mass production of next-generation biostimulators, including calcium hydroxyapatite (CaHA) and polylactic acid (PLA), as well as regenerative fillers such as dopamine-based hyaluronic acid formulations.

Cellak Bio aims to become a global aesthetics CDMO platform, extending beyond manufacturing its own branded products. From the initial design stage, the plant was optimized for aseptic filling and automated production lines with U.S. cGMP and European regulatory standards in mind.

Wonju City views the completion as a turning point in the development of its regional bio and medical industry cluster. Since establishing the Medical Device Startup Incubation Center in 1998, Wonju has grown into South Korea’s only organically developed medical device hub.

Cellak Bio plans to hire dozens of additional specialized employees as the plant begins full-scale operations. However, key challenges include the pace of GMP certification and domestic and international product approvals, as well as converting the plant’s annual capacity of 16 million units into actual utilization.